Aethlon Medical Inc AEMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Are PRTH, MG, AEMD Obtaining Fair Deals for their Shareholders?
-
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)
-
AEMD Stock Alert: Halper Sadeh LLC is Investigating Whether Aethlon Medical, Inc. is Obtaining a Fair Price for its Shareholders
-
Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
-
Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
-
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
Trading Information
- Previous Close Price
- $6.01
- Day Range
- $6.03–6.18
- 52-Week Range
- $1.41–36.84
- Bid/Ask
- $6.00 / $6.20
- Shares Outstanding
- 1.60M
- Market Cap
- $4.30M
- Volume/Avg
- 107 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.aethlonmedical.com
Valuation
|
Metric
|
AEMD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AEMD
Financial Strength
|
Metric
|
AEMD
|
|---|---|
Quick Ratio | 4.76 |
Current Ratio | 5.42 |
Interest Coverage | — |
Quick Ratio
AEMD
Profitability
|
Metric
|
AEMD
|
|---|---|
Return on Assets (Normalized) | −100.46% |
Return on Equity (Normalized) | −128.65% |
Return on Invested Capital (Normalized) | −121.65% |
Return on Assets
AEMD
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|<DHs%l@ | LOCK|!Xmf | $172B | |||
| Medtronic PLC
MDT
| LOCK|cZbBJw | LOCK|M^ZSy | $113B | |||
| Stryker Corp
SYK
| LOCK|kx%PSk$> | LOCK|dv | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|#YS?VR | LOCK|#V<d | $62B | |||
| Edwards Lifesciences Corp
EW
| LOCK|w!?Ycf< | LOCK|X<dQ& | $49B | |||
| DexCom Inc
DXCM
| LOCK|fmv<!VKY | LOCK|kHhJ | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|>PL%&Y | LOCK|Pqx | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|rb? | LOCK|!J& | $24B | |||
| Steris PLC
STE
| LOCK|&c<$Ksd | LOCK|?K>?F | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|!f>%%@<% | LOCK|B> | $17B |
United States